机构

• 上海药物研究所 [7]

采集方式

• OAI收割 [7]

内容类型

• 期刊论文 [7]

发表日期

• 2023 [1]
• 2022 [1]
• 2019 [4]
• 2018 [1]

学科主题

筛选

浏览/检索结果: 共7条，第1-7条 帮助 限定条件 专题：上海药物研究所    第一署名单位    第一作者单位    通讯作者单位     条数/页： 5101520253035404550556065707580859095100 排序方式： 请选择题名升序题名降序提交时间升序提交时间降序作者升序作者降序发表日期升序发表日期降序 YCH1899, a Highly Effective Phthalazin-1(2H)-one Derivative That Overcomes Resistance to Prior PARP Inhibitors 期刊论文  OAI收割 JOURNAL OF MEDICINAL CHEMISTRY, 2023, 页码: 20 作者:  Sun, Yuting;  Yang, Hui;  Yuan, Jiaqi;  Wang, Limin;  Song, Shanshan   |  收藏  |  浏览/下载：10/0  |  提交时间：2023/10/17 Design, synthesis and pharmacological evaluation of new PARP1 inhibitors by merging pharmacophores of olaparib and the natural product alantolactone 期刊论文  OAI收割 EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 卷号: 240, 页码: 114574 作者:  Kayumov, Muzaffar;  Jia, Li;  Pardaev, Azizbek;  Song, Shan-Shan;  Mirzaakhmedov, Sharafitdin   |  收藏  |  浏览/下载：15/0  |  提交时间：2024/03/21 PARP1  Olaparib  Alantolactone  Syntheticlethality  BRCA1/2mutant   SHR-A1403, a novel c-mesenchymal-epithelial transition factor (c-Met) antibody-drug conjugate, overcomes AZD9291 resistance in non-small cell lung cancer cells overexpressing c-Met 期刊论文  OAI收割 CANCER SCIENCE, 2019, 页码: 11 作者:  Tong, Mengya;  Gao, Mingzhao;  Xu, Yongping;  Fu, Li;  Li, Yun   |  收藏  |  浏览/下载：50/0  |  提交时间：2020/07/01 AZD9291  c-Met ADC  c-Met overexpression  resistance  SHR-A1403   Pharmacological characterization of TQ05310, a potent inhibitor of isocitrate dehydrogenase 2 R140Q and R172K mutants 期刊论文  OAI收割 CANCER SCIENCE, 2019, 页码: 9 作者:  Gao, Mingzhao;  Zhu, Hongmei;  Fu, Li;  Li, Yun;  Bao, Xubin   |  收藏  |  浏览/下载：30/0  |  提交时间：2020/07/01 AG-221  IDH2  leukemia  R140Q  R172K   Preclinical characterization of SHR6390, a novel CDK 4/6 inhibitor, invitro and in human tumor xenograft models 期刊论文  OAI收割 CANCER SCIENCE, 2019, 卷号: 110, 期号: 4, 页码: 1420-1430 作者:  Long, Fei;  He, Ye;  Fu, Haoyu;  Li, Yun;  Bao, Xubin   |  收藏  |  浏览/下载：23/0  |  提交时间：2020/07/01 breast cancer  CDK 4/6  drug resistance  palbociclib  SHR6390   Pharmacologic characterization of fluzoparib, a novel poly(ADP-ribose) polymerase inhibitor undergoing clinical trials 期刊论文  OAI收割 CANCER SCIENCE, 2019, 卷号: 110, 期号: 3, 页码: 1064-1075 作者:  Wang, Lei;  Yang, Changyong;  Xie, Chengying;  Jiang, Jiahua;  Gao, Mingzhao   |  收藏  |  浏览/下载：21/0  |  提交时间：2020/07/01 antitumor activity  fluzoparib  pharmacokinetics  poly(ADP-ribose) polymerase  toxicity   Combined inhibition of PI3K delta and FLT3 signaling exerts synergistic antitumor activity and overcomes acquired drug resistance in FLT3-activated acute myeloid leukemia 期刊论文  OAI收割 CANCER LETTERS, 2018, 卷号: 420, 页码: 49-59 作者:  He, Ye;  Sun, Liping;  Xu, Yongping;  Fu, Li;  Li, Yun   |  收藏  |  浏览/下载：34/0  |  提交时间：2019/01/08 Acute myeloid leukemia  FLT3  PI3K delta  CAL101  Synergistic effect